We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ADAKVEO (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
ADAKVEO
Date registered
Evaluation commenced
Decision date
Approval time
215 (255 working days)
Active ingredients
crizanlizumab
Registration type
NCE/NBE
Indication
ADAKVEO (concentrate solution for infusion) is indicated for the prevention of recurrent vaso-occlusive crises in patients aged 16 years and older with sickle cell disease.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.